Back to Search
Start Over
A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis.
- Source :
-
The lancet. Diabetes & endocrinology [Lancet Diabetes Endocrinol] 2024 Mar; Vol. 12 (3), pp. 209-214. Date of Electronic Publication: 2024 Jan 29. - Publication Year :
- 2024
-
Abstract
- No comprehensive classification system that guides prognosis and therapy of pituitary adenomas exists. The 2022 WHO histopathology-based classification system can only be applied to lesions that are resected, which represent few clinically significant pituitary adenomas. Many factors independent of histopathology provide mechanistic insight into causation and influence prognosis and treatment of pituitary adenomas. We propose a new approach to guide prognosis and therapy of pituitary adenomas by integrating clinical, genetic, biochemical, radiological, pathological, and molecular information for all adenomas arising from anterior pituitary cell lineages. The system uses an evidence-based scoring of risk factors to yield a cumulative score that reflects disease severity and can be used at the bedside to guide pituitary adenoma management. Once validated in prospective studies, this simple manageable classification system could provide a standardised platform for assessing disease severity, prognosis, and effects of therapy on pituitary adenomas.<br />Competing Interests: Declaration of interests We declare no competing interests.<br /> (Copyright © 2024 Elsevier Ltd. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 2213-8595
- Volume :
- 12
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- The lancet. Diabetes & endocrinology
- Publication Type :
- Academic Journal
- Accession number :
- 38301678
- Full Text :
- https://doi.org/10.1016/S2213-8587(23)00382-0